

## RESEARCH

## Open Access



# Prophylactic salpingo-oophorectomy in *BRCA1* mutation carriers and postoperative incidence of peritoneal and breast cancers

Janusz Menkiszak<sup>1</sup>, Anita Chudecka-Głaz<sup>1</sup>, Jacek Gronwald<sup>2</sup>, Aneta Cymbaluk-Płoska<sup>1</sup>, Aleksander Celewicz<sup>1\*</sup>, Maria Świniarska<sup>5</sup>, Małgorzata Wężowska<sup>1</sup>, Ryszard Bedner<sup>1</sup>, Dorota Zielińska<sup>1</sup>, Paulina Tarnowska<sup>1</sup>, Jerzy Jakubowicz<sup>3</sup> and Zbigniew Kojas<sup>4</sup>

## Abstract

**Background:** There are no effective methods of diagnosis of early-stage ovarian cancer. Conservative care over patients at high risk of ovarian and breast cancers is ineffective. Prophylactic surgery is considered the best prophylaxis among *BRCA1/BRCA2* carriers.

**Methods:** One hundred ninety-five patients, carriers of one of three most common mutations of the *BRCA1* gene (Am J Hum Genet: 66: (6)1963-1968, 2000) in the Polish population (5382insC, 4153delA and C61G), who undergone prophylactic salpingo-oophorectomy. The study group consisted of consecutive mutation carriers living in Poland, in the West Pomeranian province. Histopathological examination of the surgical material failed to reveal presence of malignancy.

**Results:** During follow-up we diagnosed two peritoneal cancers and 14 breast cancers. Diagnosis of breast cancer before prophylactic surgery increased the risk of peritoneal cancer almost three times. Time from diagnosis of breast cancer to prophylactic surgery increased the risk of peritoneal cancer after prophylactic surgery. This was strongly expressed (HR = 5.0;  $p = 0.030$ ) in cases of over five-year-long delay in prophylactic surgery. Diagnosis of breast cancer before prophylactic surgery correlated with the risk of death ( $p = 0.00010$ ). Presence of 5382insC mutation decreased and C61G mutation increased the risk of peritoneal cancer ( $p = 0.049$  vs.  $p = 0.013$ ).

**Conclusions:** Occurrence of primary peritoneal cancer after prophylactic surgery is similar to that reported in international literature. Primary breast cancer occurred less often than in international literature. We suspect that the risk of development of breast cancer among *BRCA1* carriers undergoing prophylactic surgery can differ in a population. The next goal should be to study the molecular basis for the risk of development of malignancies in any population. Carriers of *BRCA1* gene diagnosed with breast cancer should undergo prophylactic surgery within five years from the diagnosis of breast cancer.

**Keywords:** Prophylactic bilateral salpingo-oophorectomy, Risk-reducing salpingo-oophorectomy, *BRCA1*, Peritoneal cancer, Breast cancer

\* Correspondence: [a.celewicz@gmail.com](mailto:a.celewicz@gmail.com)

<sup>1</sup>Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, SPSK-2, 70-111 Szczecin Al. Powstańców Wielkopolskich 72, Szczecin, Poland  
Full list of author information is available at the end of the article



## Background

At the current state of knowledge there are no effective methods enabling identification of ovarian cancer at an early stage [1–5]. Conservative methods of prevention also failed to reduce the mortality due to ovarian cancer in a group of high-risk patients – carriers of the *BRCA1* or *BRCA2* gene mutations [6–13]. Other methods of conservative care over high-risk of ovarian and breast cancer patients (*BRCA1* or *BRCA2* carriers) have proven ineffective [1, 11, 14, 15].

According to international literature prophylactic surgery, referred to as PBSO (Prophylactic Bilateral Salpingo-Oophorectomy), RRSO (Risk-Reducing Salpingo-Oophorectomy), RRBSO (risk-reducing bilateral salpingo-oophorectomy) or BSO, is currently considered the best prophylaxis among *BRCA1/BRCA2* mutation carriers [1, 16–20].

In *BRCA1/BRCA2* mutation carriers, PBSO/RRSO not only decreases the risk of development of ovarian cancer by 80–90 % and breast cancer by 40–50 %, but also reduces mortality due to cancer of the genital tract and overall mortality [21–24].

According to Kotsopoulos et al., salpingo-oophorectomy is equally effective in prevention of breast cancer in women after natural menopause ( $p = 0.006$ ) [25]. Moreover, prophylactic salpingo-oophorectomy protects patients with breast cancer who are also *BRCA1/BRCA2* carriers from developing ovarian cancer. Metcalfe et al. demonstrated that 25 % of deaths in this group of patients, particularly with a diagnosis of stage 1 breast cancer, is caused by ovarian cancer. The fact that in this group of patients systemic treatment did not significantly influence the risk of development of ovarian cancer [26] is also an argument in favor of prophylactic surgery.

In this work we present the results of our observations in patients with mutation in *BRCA1* gene after prophylactic genital tract surgery in relation to development of peritoneal or breast cancers. We assessed selected risk factors for peritoneal cancer and compared chosen characteristics depending on the presence or absence of breast cancer diagnosis in a group of patients before prophylactic surgery.

Goal:

1. To assess the incidence of peritoneal and breast cancer among carriers of the *BRCA1* gene mutation after prophylactic salpingo-oophorectomy.
2. To analyze selected risk factors for peritoneal cancer in patients after prophylactic surgery.
3. To assess selected characteristics among patients subjected to surgery depending on the diagnosis of breast cancer before prophylactic operation.

## Methods

The material consisted of 195 patients, carriers of one of three mutations in *BRCA1* gene most commonly occurring in the Polish population (*5382insC*, *4153delA* and *C61G*) [27], subjected to prophylactic salpingo-oophorectomy. Patients underwent prophylactic surgery over a period from 15 Sept 1999 to 31 Dec 2010. Study included consecutive mutation carriers from the West Pomeranian province, Poland, treated with surgery at the Department and Clinic of Surgical Gynecology and Gynecological Oncology (adults and children) of the Pomeranian Medical University in Szczecin, who were not diagnosed with malignancy in histopathological examination of excised material. Median age of patients at the time of surgery was 47 years (31–78 years). Median follow-up time was 80 months (4–153 months).

As much as 41.03 % (80/195) of patients were treated for breast cancer before prophylactic surgery. Patients who had been treated for breast cancer before prophylactic surgery were undergoing prophylactic salpingo-oophorectomy at an older age than patients without the diagnosis of breast cancer before surgery. Both patients diagnosed with primary peritoneal cancer after prophylactic surgery, aside from salpingo-oophorectomy, had undergone hysterectomy. Proportions of specific *BRCA1* mutations were the following: 65.64 % (128/195) of patients were *5382insC* carriers, 24, 62 % (48/195) had *C61G* mutation, and 9.74 % (19/195) subjects had mutation of the *4153 DelA* type. As much as 6.67 % (13/195) of patients died during follow-up.

## Statistical analysis

All continuous variables were checked for normal distribution with Kolmogorov-Smirnov test. Such variables were described as means, standard deviations, medians, quartiles, as well as minimal and maximal values. Statistical differences between two groups were checked using Student's *t* test or Mann-Whitney's test. Non-continuous variables were described through absolute numbers and frequency of occurrence. Pearson's  $\chi^2$  test or exact Fisher's test were used to assess the relationship between non-continuous variables.

A logistic regression model was used in order to assess the risk of occurrence of a pathology depending on the presence of various factors. Results were described by relative risk (OR) with 95 % confidence interval and a *p*-value indicating statistical significance. In this model, probability was assessed using Pearson's  $\chi^2$  test or Fisher's exact two-tailed test.

Differences were considered statistically significant in all conducted tests with  $p < 0.05$ . Level of statistical significance  $p = 0.051$ – $0.099$  was considered a trend with borderline statistical significance.

Statistical analyses were performed using STATA 11 software (license no. 30110532736). The bioethics committee of the Pomeranian Medical University approved (ref. no. BN-001/202/03) for the research to be carried out.

## Results

During the follow-up time (median time was 80 months) there were 2 (2/195) cases of primary peritoneal cancer, 14 (14/195) cases of breast cancer, including 9 (9/195) primary cancers (Table 1), diagnosed in our group of *BRCA1* mutation carriers subjected to prophylactic salpingo-oophorectomy.

All breast cancers as well as primary breast cancers were diagnosed in our material more frequently than peritoneal cancer and that difference was statistically significant, with  $p = 0.0022$  (OR = 7.46; 95 % CI: 1.67–68.29) vs.  $p = 0.0323$  (OR = 4.67; 95 % CI: 1.10–44.10). Primary breast cancer was 2.27 times more frequent than breast cancer recurrence, but that relationship was not statistically significant (OR = 2.27; 95 % CI: 0.71–8.49).

Time of cancer diagnosis after prophylactic surgery was significantly shorter among patients with *5382insC* mutation compared with *C61G* and *4153DelA* mutations combined,  $p = 0.0271$  (median: 23 vs. 62 months).

Diagnosis of breast cancer in a patient before prophylactic surgery increased the risk of peritoneal cancer almost three times, but this characteristic was on the border of statistical significance ( $p = 0.088$ ). Carrying a *5382insC* mutation decreased the probability of peritoneal cancer, while *C61G* mutation increased such likelihood,  $p = 0.049$  and  $p = 0.013$ , respectively. Among carriers of *4153DelA* mutation the risk of development of peritoneal cancer was neither increased nor decreased; that characteristic was not statistically significant (Table 2).

Time from the diagnosis of breast cancer in a patient before prophylactic surgery to the procedure itself was a feature increasing the risk of peritoneal cancer in a significant manner. That characteristic was particularly strong (HR = 5.0;  $p = 0.030$ ) in cases where the decision of prophylactic surgery was delayed by more than five years (Table 3).

Among all features selected for analysis among *BRCA1* carriers diagnosed with breast cancer before prophylactic surgery, only the survival feature was statistically significant ( $p = 0.00010$ ). Patients diagnosed with cancer before prophylactic surgery died more frequently. In that group of patients increased probability of development of any cancer or peritoneal cancer was on the border of statistical significance. Remaining features subjected to analysis, including type of mutation, were not statistically significant (Table 4).

## Discussion

In 1982 Jeanne Tobacman et al. described the first three cases of peritoneal cancer after prophylactic oophorectomy among 28 patients from families at high risk of ovarian cancer [28]. Many studies have been published since then. Sitzmann and Wiebke [29] point to several important facts in one of the most recent metaanalyses evaluating, among other things, the frequency of occurrence of peritoneal cancer after salpingo-oophorectomy in patients with *BRCA1/BRCA2* mutation. Firstly, a great majority of authors report the number of diagnosed peritoneal cancers at a level of 0.8–1.8 % [22, 30–36].

Casey et al. diagnosed 5 cases of peritoneal cancer among 118 carriers of *BRCA1* mutation. In one case the patient had undergone oviduct-sparing surgery [37]. Among three cases of peritoneal cancer diagnosed in *BRCA1* carriers after PBSO, Mæhle et al. associated that fact with presence of ovarian tissue left behind after previous surgeries [38]. Oliver et al. diagnosed 11.5 % (3/26 – *BRCA1* mutation) of peritoneal cancers after prophylactic surgery, but the study group consisted of patients after oviduct-sparing surgery. In the second group of patients subjected to salpingo-oophorectomy the same authors did not find any cases of peritoneal cancer during the follow-up period (0/58 – *BRCA1*). However, researchers admit that it might have been due to very short mean follow-up time, which amounted to 12 months [39]. Likewise, after 16 months of follow-up, Gaarenstroom et al. did not diagnose peritoneal cancer in any of 114 patients (57 patients were carriers of *BRCA1* mutation) following prophylactic salpingo-oophorectomy [40].

**Table 1** Number of cancers and type of organ affected by cancer in patients followed up after prophylactic surgery

		No.			
		Number %/(n)	All primary breast cancers %/(n)	All breast cancers %/(n)	All primary peritoneal and breast cancers %/(n)
Organ					Total %/(n)
Peritoneum		1.03 % (2/195)	-	-	5.64 % (11/195)
Breast	Primary	3.08 % (6/195)	4.63 % (9/195)	7.18 % (14/195)	8.21 % (16/195)
	II – primary	1.54 % (3/195)			
	Recurrence	2.56 % (5/195)	N/A		
					N/A

**Table 2** Risk of occurrence of peritoneal cancer in the whole group of patients ( $n = 195$ ) depending on the characteristics assessed with Cox regression model

Dependent variable	Data	HR	95 % CI	p
	Risk factors			
Peritoneal cancer	Breast cancer before surgery	2.95	0.75 175.43	0.088
	Age at time of surgery (years)	1.15	0.96 1.37	0.125
	5382insC mutation	0.25	0.00 0.99	0.049
	C61G mutation	6.39	1.62 379.51	0.013
	4153DelA mutation	0.90	0.07 18.50	0.641

Laki et al. did not find any cases of peritoneal cancer among their patients following mean follow-up time of 40 months either [41]. Similarly, there were no cases of primary peritoneal cancer in an 8.17-year follow-up in a study by Evans et al. that included *BRCA1/BRCA2* mutation carriers (160 patients, including 104 subjects with *BRCA1* mutation) after salpingo-oophorectomy [42].

Authors who failed to find cases of peritoneal cancer after prophylactic salpingo-oophorectomy most often explain it by short follow-up time. Such an argument is no longer valid for the analysis of work by Evans et al. Small size of the group is also often given as a reason for the lack of such a finding [42].

In our analysis we acquired a result almost identical with regard to the frequency of diagnosis of peritoneal cancer among patients after salpingo-oophorectomy to that obtained by Rhiem et al. – 1.03 % vs. 1.09 % (2/195 vs. 1/92 – *BRCA1* gene mutations). The time of the first diagnosis of peritoneal cancer was also similar – in our material it amounted to 30 months, while according to Rhiem et al. – 26 months [34]. In our study the second peritoneal cancer was diagnosed after 62 months.

The second, very important conclusion ensuing from this research is such that after prophylactic surgery peritoneal cancer develops more frequently in *BRCA1* mutation carriers. Peritoneal cancer was very rare among patients with *BRCA2* mutation. In their metaanalysis, Sitzmann and

Wiebke [29] presented results of 12 research teams and in only one study by Finsch et al. peritoneal cancer was found in a patient with a mutation in the *BRCA2* gene [33].

However, it should be emphasized, that while there are thousands of examined patients and mean follow-up time from prophylactic surgery to the diagnosis of peritoneal cancer exceeds 6 years, the proportion of mutations in both *BRCA* genes found in patients with primary peritoneal cancer diagnosed after salpingo-oophorectomy has evidently changed – 28 *BRCA1* vs. *BRCA2* [21].

Due to a small number of subjects after prophylactic surgery with *BRCA2* gene mutation, we did not take their data into consideration.

In our material we diagnosed 14 cases (14/195 = 7.18 %) of breast cancer, including 6 cases in patients without the diagnosis of breast cancer before prophylactic surgery, 3 cases of second primary breast cancer and 5 cases of breast cancer recurrence. Thus, primary breast cancers identified during the follow-up time constituted only 4.63 % (9/195) of all cases (Table 1).

Results obtained for primary breast cancers in our material were somewhat smaller than values reported by Casey et al. – 4.63 % vs. 5.93 % (7/118 – *BRCA1* mutation) over a shorter median follow-up time – 6.67 vs. 8.3 years, respectively [37].

Similar overall results were obtained by Kauff et al. – 7.89 % (15/190 – *BRCA1* mutation), with mean follow-up

**Table 3** Risk of occurrence of peritoneal cancer in the group of patients with diagnosed breast cancer before prophylactic surgery ( $n = 80$ ) depending on the characteristics assessed with Cox regression model

Dependent variable	Data	Risk factor	HR	CI 95 %	p
	Characteristic				
Peritoneal cancer	Time from diagnosis of breast cancer prior to prophylactic surgery to prophylactic surgery	Years	1.14	1.00 1.29	0.043
	Time from diagnosis of breast cancer prior to prophylactic surgery to prophylactic surgery	Years >=5 vs. <5	5.00	1.23 300.17	0.030
	Age at the moment of breast cancer diagnosis in a patient before prophylactic surgery	Years	0.93	0.75 1.14	0.488

**Table 4** Evaluation of selected characteristics among patients depending on the diagnosis of breast cancer before prophylactic surgery

Characteristic	Breast cancer before surgery					p	
	Not identified <i>n</i> = 115		Identified <i>n</i> = 80		N		
Death	1	0.87 %	12	15.00 %	13	<i>p</i> = 0.00010	
Development of cancer	6	5.22 %	10	12.50 %	16	<i>p</i> = 0.06835	
Development of peritoneal cancer	0	0.00 %	2	2.50 %	2	<i>p</i> = 0.08832	
Development of breast cancer	6	5.22 %	8	10.00 %	14	<i>p</i> = 0.20318	
Development of primary breast cancer	6	5.22 %	3	3.75 %	9	<i>p</i> = 0.63096	
	<i>5382insC</i>	78	67.83 %	50	62.50 %	128	<i>p</i> = 0.44111
Type of mutation	<i>C61G</i>	24	20.87 %	24	30.00 %	48	<i>p</i> = 0.14543
	<i>4153DelA</i>	13	11.30 %	6	7.50 %	19	<i>p</i> = 0.37823

time shorter almost by half [32], and Powell et al. – 6.35 % (4/63) among *BRCA1* carriers, with median observation time almost 1/3 shorter compared to our study. Moreover, in a detailed analysis researchers emphasize that most of these cases were breast cancer recurrences [36]. Domchek et al. acquired significantly higher results with respect to breast cancer diagnoses among *BRCA1* mutation carriers subjected to prophylactic salpingo-oophorectomy over an almost 5-year-long mean follow-up time – 13.6 % (51/374 – *BRCA1*). Moreover, quantitative values were comparable regardless of a diagnosis of breast cancer before prophylactic surgery [22].

Similarly high values were obtained by Fakkert et al. – 11.54 % (12/104 – *BRCA1*) over a median 3-year observation time [43] and Laki et al. – 10.71 % (6/56 – *BRCA1*) [41].

Ramon Y Cajal et al. presented very high quantitative values – researchers diagnosed as many as 5 cases of breast cancer among 25 carriers of *BRCA1* gene mutation (20 %–5/25) subjected to prophylactic salpingo-oophorectomy. In that case median follow-up time was 49 months [44].

Likewise, a very high (over 20 %) proportion of breast cancer diagnoses among *BRCA1* mutation carriers after prophylactic bilateral oophorectomy was obtained by Shah et al. with a median follow-up time from surgery to the diagnosis of cancer amounting to 3.6 years [45].

Available literature is in agreement with regard to higher incidence of breast cancer than peritoneal cancer among *BRCA1* carriers undergoing prophylactic salpingo-oophorectomy [22, 32, 36, 41, 43].

Since the differing results of studies on breast cancer in *BRCA1* carriers undergoing prophylactic salpingo-oophorectomy came from multi-center, multi-national trials performed in various countries: USA, Canada, Netherlands, France, Norway, Spain, Australia and New Zealand, we believe that it is necessary to examine molecular background in all populations, particularly for such a common malignancy as breast cancer.

There were few publications on the influence of breast cancer diagnosis among *BRCA1* gene mutation carriers before prophylactic surgery and the incidence of peritoneal cancer in the postoperative period. There are also few publications regarding the influence of the time from diagnosis of breast cancer to prophylactic surgery and the diagnosis of peritoneal cancer in the postoperative period.

In our material the diagnosis of breast cancer before prophylactic surgery was associated with an almost three-fold increase in the risk of peritoneal cancer. However, that correlation was not statistically significant. Domchek et al. acquired an opposite result. Peritoneal cancer was found less often in patients with *BRCA1* mutation and breast cancer diagnosis before surgery than in patients without breast cancer prior to surgery – 1.18 % vs. 1.75 %. Researchers demonstrated also that prophylactic salpingo-oophorectomy decreased the risk of primary peritoneal cancer among patients without previous diagnosis of breast cancer by 70 % and in patients diagnosed with breast cancer prior to prophylactic surgery by 85 % [22].

In our opinion, dissimilarities in our conclusions with regard to the risk of development of peritoneal cancer among patients without the diagnosis of breast cancer prior to prophylactic surgery may ensue from different numbers of diagnosed peritoneal cancer cases – 2 vs. 10 patients in a study by Domchek et al. Moreover, in our study both patients diagnosed with primary peritoneal cancer, who had been treated for breast cancer prior to prophylactic surgery, decided to have the salpingo-oophorectomy performed after the age of 50. Therefore, surgery might no longer serve a protective role in development of peritoneal cancer postoperatively.

Continuing the subject of the influence of breast cancer diagnosis before prophylactic surgery, among six analyzed features we found only the risk of death to be statistically significant. Patient survival after prophylactic surgeries will be the subject of another publication.



The topic of the influence of *BRCA1* gene mutation on examined characteristics is highly problematic to discuss. Although the type of mutation most commonly identified in Polish population - *5382insC* – is also found among Jewish people, Ashkenazi Jews in particular [46], available literature lacks the data for discussion.

## Conclusions

Based on the analysis of gathered material and existing literature we found that in our data the incidence of primary peritoneal cancer after prophylactic surgery is similar to that reported in international literature. What differs our material from reports in international literature is the occurrence of primary breast cancer – it was significantly less frequent. Another conclusion is that it cannot be excluded that the risk of breast cancer development among constitutional *BRCA1* gene mutation carriers subjected to prophylactic surgery varies in a population. The next goal in research should be to examine molecular background with regard to the risk of malignancy in every population. It is also important that carriers of the *BRCA1* gene mutation diagnosed with breast cancer should be subjected to prophylactic surgery within less than five years from the diagnosis of breast cancer, as the risk of peritoneal cancer increases significantly after that period.

## Consent

Written informed consent was obtained from the patient for the publication of this report and any accompanying images.

## Competing interests

The authors declare that they have no competing interests.

## Authors' contributions

JM – first author of the manuscript, gave the idea for the whole article. Data collection and statistical analysis. AC-G – co-author of the text, data collection, performed the prophylactic operations. JG – co-author of the text, coordinated detection of the mutation carriers and indications for prophylactic operations. AC-P – data collection, performed the prophylactic operations. AC – co-author of the text, international literature collection, manuscript submission. MŚ – Follow-up coordinator, analysis of the results. MW – data collection, performed the prophylactic operations. RB – data collection, performed the prophylactic operations. DZ – analysis and interpretation of results. PT – statistical analysis, correction of the manuscript. JJ – Follow-up coordinator in Cracow. ZK – data collection, performed the prophylactic operations in Cracow. All authors read and approved the final manuscript.

## Funding

The authors declare there was no funding concerning this article.

## Author details

<sup>1</sup>Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, SPSK-2, 70-111 Szczecin Al. Powstańców Wielkopolskich 72, Szczecin, Poland. <sup>2</sup>Department of Genetics and Pathology; International Hereditary Cancer Center, Pomeranian Medical University, Al. Powstańców Wielkopolskich 72, 70-111 Szczecin, Poland. <sup>3</sup>Radiation Oncology Department, Centre of Oncology, Maria Skłodowska-Curie Memorial Institute Cracow Branch, Garncarska 11, 31-115 Kraków, Poland. <sup>4</sup>Department of Gynecologic Oncology, Centre of

Oncology, Maria Skłodowska-Curie Memorial Institute, Cracow Branch, Garncarska 11, 31-115 Kraków, Poland. <sup>5</sup>Department of the Clinical Oncology the West Pomeranian Centre of the Oncology in Szczecin, ul. Strzałowska 22, 71-730 Szczecin, Poland.

Received: 26 November 2015 Accepted: 19 February 2016

Published online: 29 February 2016

## References

- Walker JL, Powell CB, Chen LM, Carter J, Bae J, Jump VL, Parker LP, et al. Society of Gynecologic Oncology Recommendations for the Prevention of Ovarian Cancer. *Cancer*. 2015;121:2108–20.
- Howard AF, Balneaves LG, Bottruff JL, et al. Preserving the self: the process of decision making about hereditary breast cancer and ovarian cancer risk reduction. *Qual Health Res*. 2011;21(4):502–19.
- Evans DG, Gaarenstroom KN, Stirling D, et al. Screening for familial ovarian cancer: poor survival of *BRCA1/2* related cancers. *J Med Genet*. 2009;46(9):593–7.
- Brown PO, Palmer C. The preclinical natural history of serous ovarian cancer: defining the target for early detection. *PLoS Med*. 2009;6(7):e1000114.
- Gulden C, Olopade OL. Risk assessment and genetic testing for ovarian cancer. *AJR Am J Roentgenol*. 2010;194(2):309–10.
- Goff BA, Lowe KA, Kane JC, Robertson MD, Gaul MA, Andersen MR. Symptom triggered screening for ovarian cancer: a pilot study of feasibility and acceptability. *Gynecol Oncol*. 2012;24:230–5.
- Goff BA. Ovarian cancer: screening and early detection. *Obstet Gynecol Clin North Am*. 2012;39:183–94.
- Goff BA, Matthews B, Andrilla CH, et al. How are symptoms of ovarian cancer managed? A study of primary care physicians. *Cancer*. 2011;117:4414–23.
- Goff B. Symptoms associated with ovarian cancer. *Clin Obstet Gynecol*. 2012;55:36–42.
- Andersen MR, Goff BA, Lowe KA, et al. Combining a symptoms index with CA 125 to improve detection of ovarian cancer. *Cancer*. 2008;113:484–9.
- Buyss SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. *JAMA*. 2011;305:2295–303.
- Gilbert L, Basso O, Sampalis J, et al. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DoVE pilot project. *Lancet Oncol*. 2012;13:285–91.
- Andersen MR, Goff BA, Lowe KA, et al. Use of a symptom index, CA125, and HE4 to predict ovarian cancer. *Gynecol Oncol*. 2010;116:378–83.
- Synowiec A, Wcisło G, Bodnar L, Gasowska-Bodnar A, Szczylik C. Screening for ovarian cancer in *BRCA1/BRCA2* mutation carriers. *Ginek Pol*. 2014;85(5):377–81.
- M dry R, Markowska A. Reduction of risk of developing *BRCA*-dependent cancer in *BRCA1/2* mutation carriers – novel approach to old paradigm. *Curr Gynecol Oncol*. 2010;8(3):188–99.
- Greene MH, Piedmonte M, Alberts D, et al. A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study. *Cancer Epidemiol Biomarkers Prev*. 2008;17:594–604.
- Greene MH, Mai PL, Schwartz PE. Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in *BRCA1/2* mutation carriers? *Am J Obstet Gynecol*. 2011;204(1):19.e1–6.
- Kauff ND, Barakat RR. Risk-reducing salpingo-oophorectomy in patients with germline mutations in *BRCA1* or *BRCA2*. *J Clin Oncol*. 2007;25:2921–7.
- Long KC, Kauff ND. Hereditary ovarian cancer: recent molecular insights and their impact on screening strategies. *Curr Opin Oncol*. 2011;23(5):526–30. Review.
- Berek JS, Chalas E, Edelson M, et al. Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer. Society of Gynecologic Oncologists Clinical Practice Committee. *Obstet Gynecol*. 2010;116(3):733–43.
- Finch AP, Lubinski J, Møller P, Singer CF, Karlan B, Senter L, et al. Impact of oophorectomy on cancer incidence and mortality in women with a *BRCA1* or *BRCA2* mutation. *J Clin Oncol*. 2014;32(15):1547–53.

22. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. *JAMA*. 2010;304:967–75.
23. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. *J Natl Cancer Inst*. 2009;101(2):80–7.
24. Kurian AW, Sigal BM, Plevritis SK. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. *J Clin Oncol*. 2010;28(2):222–31.
25. Kotsopoulos J, Lubinski J, Lynch HT, Kim-Sing C, Neuhausen S, Demsky R, et al. Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiol Biomarkers Prev*. 2012;21(7):1089–96.
26. Metcalfe KA, Lynch HT, Ghadirian P, Tung N, Olivetto IA, Foulkes WD, et al. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. *Gynecol Oncol*. 2005;96(1):222–6.
27. Górski B, Byrski T, Huzarski T, et al. Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. *Am J Hum Genet*. 2000;66(6):1963–8.
28. Tobacman JK, Greene MH, Tucker MA, Costa J, Kase R, Fraumeni Jr JF. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. *Lancet*. 1982;2(8302):795–7.
29. Sitzmann JV, Wiebke EA. Risk-reducing appendectomy and the elimination of BRCA1-associated intraperitoneal cancer. *JAMA Surg*. 2013;148(3):285–91.
30. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, et al. Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. *N Engl J Med*. 2002;346(21):1616–22.
31. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. *N Engl J Med*. 2002;346(21):1609–15.
32. Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. *J Clin Oncol*. 2008;26(8):1331–7.
33. Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, et al. Hereditary Ovarian Cancer Clinical Study Group. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. *JAMA*. 2006;296(2):185–92.
34. Rhiem K, Foth D, Wappenschmidt B, Gevensleben H, Büttner R, Ulrich U, et al. Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers. *Arch Gynecol Obstet*. 2011;283(3):623–7.
35. Kiely BE, Friedlander ML, Milne RL, Stanhope L, Russell P, Jenkins MA, et al. kConFab Investigators, Hopper JL, Phillips KA. Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer. *Fam Cancer*. 2011;10(3):505–14.
36. Powell CB, Chen LM, McLennan J, Crawford B, Zaloudek C, Rabban JT, et al. Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol. *Int J Gynecol Cancer*. 2011;21(5):846–51.
37. Casey MJ, Synder C, Bewtra C, Narod SA, Watson P, Lynch HT. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. *Gynecol Oncol*. 2005;97(2):457–67.
38. Mæhle L, Apold J, Paulsen T, Hagen B, Løvslett K, Fiane B, et al. High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers. *Clin Cancer Res*. 2008;14(22):7569–73.
39. Olivier RI, van Beurden M, Lubsen MA, Rookus MA, Mooij TM, van de Vijver MJ, et al. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. *Br J Cancer*. 2004;90(8):1492–7.
40. Gaarenstroom KN, van der Hiel B, Tollenaar RA, Vink GR, Jansen FW, van Asperen CJ, et al. Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study. *Int J Gynecol Cancer*. 2006;16(1):54–9.
41. Laki F, Kirova YM, This P, Plancher C, Asselain B, Sastre X, et al. IC-BOCRSG IC-BOCRSG: Institut Curie - Breast Ovary Cancer Risk Study Group. Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation. *Cancer*. 2007;109(9):1784–90.
42. Evans DG, Clayton R, Donnai P, Shenton A, Laloo F. Risk-reducing surgery for ovarian cancer: outcomes in 300 surgeries suggest a low peritoneal primary risk. *Eur J Hum Genet*. 2009;17(11):1381–5.
43. Fakkert IE, Mourits MJ, Jansen L, van der Kolk DM, Meijer K, Oosterwijk JC, et al. Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers. *Cancer Prev Res (Phila)*. 2012;5(11):1291–7.
44. Ramon Y, Cajal T, Torres A, Alonso C, Fisas D, Ojeda B, et al. Risk factors associated with the occurrence of breast cancer after bilateral salpingo-oophorectomy in high-risk women. *Cancer Epidemiol*. 2011;35(1):78–82.
45. Shah P, Rosen M, Stopfer J, Siegfried J, Kaltman R, Mason B, et al. Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence. *Breast Cancer Res Treat*. 2009;118(3):539–46.
46. Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. *Clin Cancer Res*. 2002;8(12):3776–81.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

